On July 26, 2021 Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, reported that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021 (Press release, Agenus, JUL 26, 2021, View Source [SID1234585236]). Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and to provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call
Dial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International).
Conference ID number: 3686849.

Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at View Source and via View Source

On July 26, 2021 Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, reported that it filed to raise $300 million in a Hong Kong IPO. Sirnaomics has two siRNA therapeutics that target TGF-β1 and COX-2 for either local or systemic administration to treat cancers and fibrotic diseases (Press release, Sirnaomics, JUL 26, 2021, View Source [SID1234585221]). Both are in Phase II trials in the US and China. The initial filing did not announce a financial goal for the offering, but data in the prospectus implied a $300 million target. Sirnaomics completed a $105 million Series E round earlier this month after raising the same amount in a Series D last year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 26, 2021 Eversana, a provider of global commercial services to the life sciences industry, reported tha it has acquired Accelera Canada, along with its partner companies Patient Access Solutions, Podium Strategic Partners, Inc. and Advocacy Solutions (Press release, EVERSANA, JUL 26, 2021, View Source [SID1234585220]). Based in Toronto, Accelera Canada is an end-to-end commercialization service provider that is helping 50 companies operate in the Canadian pharma market. Financial terms of the deal were not disclosed, but with this latest development, Eversana is able to expand its Canada-based team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are rapidly scaling our global commercialization services by finding and partnering with the best service providers in every region," says Jim Lang, Eversana’s CEO. "The Accelera Canada team adds decades of experience navigating the fields of product launch, market access and patient advocacy in the Canadian marketplace, making them the perfect partner to support the growing needs of our clients."

Accelera Canada’s founding partners and owners, Michael Cloutier, Charles Pirraglia, Deborah Brown, Lindy Forte and Ryan Clarke, as well as extended team members, will join Eversana immediately. And over the next few months, legacy brands will be integrated.

On July 26, 2021 Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), reported that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021 (Press release, Coherus Biosciences, JUL 26, 2021, View Source [SID1234585206]). Starting at 5 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After releasing second quarter financial results, the Company will post them on the Coherus website at View Source

Conference Call Information

Webcast: View Source

Please dial-in 15 minutes early to ensure a timely connection to the call.

On July 26, 2021 EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, reported the acquisition of Accelera Canada and its partner companies Patient Access Solutions, Podium Strategic Partners, Inc., and Advocacy Solutions (Press release, EVERSANA, JUL 26, 2021, View Source [SID1234585205]). Headquartered in Toronto, Accelera Canada is recognized as the country’s leading end-to-end commercialization service provider, helping more than 50 companies successfully operate in the Canadian pharmaceutical market. The acquisition further propels EVERSANA’s expansion of services worldwide, including recent investments in Europe and Asia Pacific.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are rapidly scaling our global commercialization services by finding and partnering with the best service providers in every region," said Jim Lang, CEO, EVERSANA. "The Accelera Canada team adds decades of experience navigating the complexity of product launch, market access and patient advocacy in the Canadian marketplace, making them the perfect partner to support the growing needs of our clients."

With this latest acquisition, EVERSANA adds depth to its consulting, patient advocacy, patient support and market access services and further expands its team based in Canada, which includes more than 150 colleagues in Ontario and Nova Scotia. EVERSANA previously acquired Canada-based Cornerstone Research Group in 2019.

"Across our partner companies, we’ve experienced significant growth over the past 15 years, navigating the nuances of the Canadian health care market. Now with the collective power of EVERSANA, our clients have immediate access to a more comprehensive end-to-end commercialization solution to meet any global challenge," said Michael Cloutier, founding partner & business development lead, Accelera Canada. "We’re thrilled to expand with a company that shares our values in client service and our commitment to accelerating Canadian patient access to the latest medical advances."

The company’s founding partners and owners, Michael Cloutier, Charles Pirraglia, Deborah Brown, Lindy Forte and Ryan Clarke, as well as extended team members, will join EVERSANA immediately. Legacy brands will be integrated into EVERSANA in the coming months.

Financial details of the acquisition are not being disclosed.